Lower optimal dose of amrubicin for relapsed small-cell lung cancer: a retrospective study

ConclusionTreatment with AMR between 30 and 35  mg/m2 showed relatively mild hematologic toxicity compared with AMR at 40  mg/m2, without any significant difference in efficacy. Lower dose of AMR for relapsed SCLC could be a promising treatment option.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research